Automated manufacturing of CAR NK cells WEBINAR

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=6nKQRN_JyyY

Learn about the current status of CAR engineered NK cells as an adoptive, cell-based immunotherapy, alongside the strategies developed for CAR NK cell generation. • Find more Miltenyi Biotec webinars at https://www.miltenyibiotec.com/resour... • With recent advances in immuno-oncology research, CAR NK cells have been highlighted as a promising approach for a cell-based immunotherapy. The critical role of immune cells in cancer therapy has been validated, and adoptive cell therapies are more frequently a treatment of choice. With increased amounts of clinical research taking place, we will review the current strategies of CAR NK cell generation. • Finally, we will observe Miltenyi Biotec’s solutions how we can introduce the new CliniMACS Prodigy Platform, a unique platform that allows the generation of gene-modified CAR NK cells in a standardized and fully automated fashion. • Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

#############################

New on site